Literature DB >> 15730400

Altered CD46-mediated T cell co-stimulation in haemodialysis patients.

P-T Brinkkoetter1, S Marinaki, U Gottmann, S Fleckenstein, C Stump, F J Van Der Woude, C Braun, B A Yard.   

Abstract

While most of our understanding of immune dysfunction in dialysis patients involves alterations in CD28-CD80/86 signalling, nothing is known of CD46-mediated co-stimulation of T cells in these patients. Because C3b/C4b bind to CD46 and complement activation occurs during haemodialysis (HD), we addressed whether CD46-mediated T cell activation is altered in HD (n = 9), peritoneal dialysis (PD) (n = 10) and predialysis patients (n = 8) compared to healthy controls (HC) (n = 8). T cell surface markers, T cell proliferation and interleukin (IL)-10 production were studied in CD4(+)T cells. In addition, CD46 splice-variants and IL-10 promoter gene polymorphisms were studied by reverse transcription (RT) or amplification refractory mutation system-polymerase chain reaction (ARMS-PCR), respectively. In all uraemic patients, irrespective of the stage of renal insufficiency or dialysis modality, a significant increase in the percentage of CD25 positivity in naive CD4(+)T cells was found (64% +/- 21%versus 23% +/- 18%, P < 0.001). Lymphocytes of HD patients proliferated in greater numbers and produced more IL-10 after co-stimulation with anti-CD46 than after co-stimulation with anti-CD28. This was also found in CD4(+)T cells of PD patients, albeit to a lesser extent. In contrast, with T cells of predialysis patients and of HC, co-stimulation via CD28 was more efficient. The observed alterations in T cell proliferation and IL-10 production were associated neither with CD46 splice variants nor with IL-10 promoter gene polymorphisms. Lymphocytes of HD patients show an increased response on CD46 co-stimulation. These data suggest that ongoing complement activation in HD patients may lead to alterations in acquired immunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15730400      PMCID: PMC1809311          DOI: 10.1111/j.1365-2249.2005.02705.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  34 in total

1.  CD46/CD3 costimulation induces morphological changes of human T cells and activation of Vav, Rac, and extracellular signal-regulated kinase mitogen-activated protein kinase.

Authors:  Y Zaffran; O Destaing; A Roux; S Ory; T Nheu; P Jurdic; C Rabourdin-Combe; A L Astier
Journal:  J Immunol       Date:  2001-12-15       Impact factor: 5.422

2.  Membrane cofactor protein (MCP; CD46): isoform-specific tyrosine phosphorylation.

Authors:  G Wang; M K Liszewski; A C Chan; J P Atkinson
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

3.  T cells activate the tumor necrosis factor-alpha system during hemodialysis, resulting in tachyphylaxis.

Authors:  I C van Riemsdijk; C C Baan; E H Loonen; C J Knoop; G Navarro Betonico; H G Niesters; R Zietse; W Weimar
Journal:  Kidney Int       Date:  2001-03       Impact factor: 10.612

4.  Catecholamines induce IL-10 release in patients suffering from acute myocardial infarction by transactivating its promoter in monocytic but not in T-cells.

Authors:  U Riese; S Brenner; W D Döcke; S Prösch; P Reinke; M Oppert; H D Volk; C Platzer
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

5.  Polarization of T-helper lymphocytes toward the Th2 phenotype in uremic patients.

Authors:  C Libetta; T Rampino; A Dal Canton
Journal:  Am J Kidney Dis       Date:  2001-08       Impact factor: 8.860

6.  The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients.

Authors:  M Girndt; U Sester; M Sester; E Deman; C Ulrich; H Kaul; H Köhler
Journal:  Kidney Int       Date:  2001-12       Impact factor: 10.612

7.  Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect.

Authors:  M Girndt; M Sester; U Sester; H Kaul; H Köhler
Journal:  Kidney Int       Date:  2001-04       Impact factor: 10.612

8.  Deaths within 90 days from starting renal replacement therapy in the ERA-EDTA Registry between 1990 and 1992.

Authors:  D Tsakiris; E H Jones; J D Briggs; C G Elinder; O Mehls; S Mendel; G Piccoli; S P Rigden; J Pintos dos Santos; K Simpson; Y Vanrenterghem
Journal:  Nephrol Dial Transplant       Date:  1999-10       Impact factor: 5.992

9.  Mortality caused by sepsis in patients with end-stage renal disease compared with the general population.

Authors:  M J Sarnak; B L Jaber
Journal:  Kidney Int       Date:  2000-10       Impact factor: 10.612

Review 10.  End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link?

Authors:  M Arici; J Walls
Journal:  Kidney Int       Date:  2001-02       Impact factor: 10.612

View more
  7 in total

1.  Decreased percentage of peripheral naïve T cells is independently associated with ischemic stroke in patients on hemodialysis.

Authors:  Rongyi Chen; Jiachang Hu; Fangfang Xiang; Xiao Tan; Bo Shen; Zhonghua Liu; Wenlv Lv; Xiaoqiang Ding; Xuesen Cao; Jianzhou Zou
Journal:  Int Urol Nephrol       Date:  2017-09-15       Impact factor: 2.370

2.  Inhibition of CXCL10 release by monomeric C3bi and C4b.

Authors:  Y Takeda; K Kaneda; F Jimma; N Shiobara; M Hidaka; A R Saniabadi; I Wakabayashi
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

3.  Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis.

Authors:  Anne L Astier; Gregory Meiffren; Samuel Freeman; David A Hafler
Journal:  J Clin Invest       Date:  2006-11-09       Impact factor: 14.808

4.  Mechanism of neuroinflammation: enhanced cytotoxicity and IL-17 production via CD46 binding.

Authors:  Karen Yao; Jhanelle Graham; Yoshimi Akahata; Unsong Oh; Steven Jacobson
Journal:  J Neuroimmune Pharmacol       Date:  2010-07-27       Impact factor: 4.147

Review 5.  Immune cell dysfunction and inflammation in end-stage renal disease.

Authors:  Michiel G H Betjes
Journal:  Nat Rev Nephrol       Date:  2013-03-19       Impact factor: 28.314

6.  Clinical impact of advanced chronic kidney disease in patients with non-HIV pulmonary cryptococcosis.

Authors:  Hiroki Tashiro; Tetsuro Haraguchi; Koichiro Takahashi; Hironori Sadamatsu; Ryo Tajiri; Ayako Takamori; Shinya Kimura; Naoko Sueoka-Aragane
Journal:  BMC Pulm Med       Date:  2020-04-29       Impact factor: 3.317

7.  Increased mortality associated with uncontrolled diabetes mellitus in patients with pulmonary cryptococcosis: a single US cohort study.

Authors:  Solana Archuleta; Amal A Gharamti; Stefan Sillau; Paula Castellanos; Sindhu Chadalawada; William Mundo; Mehdi Bandali; Jose Oñate; Ernesto Martínez; Daniel B Chastain; Kristen DeSanto; Leland Shapiro; Ilan S Schwartz; Carlos Franco-Paredes; Andrés F Henao-Martínez
Journal:  Ther Adv Infect Dis       Date:  2021-03-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.